Heparins in diabetic microangiopathy: Rationale and preliminary clinical results

Haemostasis

Volumn 29, Issue SUPPL. 1, 1999, Pages 61-67

  Van Der Woude, Fokko J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Diabetes nephropathy; Glycosaminoglycans; Heparan sulphate; Heparins; Microangiopathy

Indexed keywords

ALBUMIN; DANAPAROID; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN;

CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; RETINOPATHY; SULFATION;

EID: 0033402947     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054113     Document Type: Conference Paper

References (48)

1. Renine Foundation: De ontwikkeling van het nierfunctie-vervangingsprogramma in Nederland. Statistisch verslag. Rotterdam, Erasmus University Rotterdam, 1998.
2. The 'United States Renal Data System' is available on: URL: http:/ /www.med.umich.edu/usrds. Chapter II: Incidence and prevalence of ESRD, 1999.
3. Pastan S, Bailey J: Dialysis therapy. N Engl J Med 1998;338:1428-1437.
4. DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
6. Mogensen CE: How to protect the kidney in diabetic patients. Diabetes 1997;46(suppl 2):S104-S111.
7. Seaquist ER, Goetz FC, Rich S, Barbosa J: Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989;320: 1161-1165.
8. Pettitt DJ, Nelson RG, Saad MF, Bennett PH, Knowler WC: Diabetes and obesity in the offspring of Pima Indian women with diabetes during pregnancy. Diabetes Care 1993;16: 310-314.
9. Borch-Johnsen K, Norgaard K, Hommel E, Mathiesen ER, Jensen JS, Deckert T, Parving HH: Is diabetic nephropathy an inherited complication? Kidney Int 1991;41:719-722.
10. Parving HH, Tarnow L, Rossing P: Genetics of diabetic nephropathy. J Am Soc Nephrol 1996;7:2509-2517.
11. Parving HH, Osterby R, Anderson PW, Hsueh W: Diabetic nephropathy; in Brenner BM (ed): The Kidney, ed 5. Philadelphia. Saunders, 1996, pp 1864-1892.
12. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH: Predictors of mortality in insulin dependent diabetes: 10 year observational follow-up study. BMJ 1996;313:779-784.
13. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Kotbed-Enevoldsen A: Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989;32:219-226.
14. Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang L: Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? J Clin Invest 1997;100:S67-S75.
15. Van der Woude FJ, van Det NF: Heparan sulphate proteoglycans and diabetic nephropathy. Exp Nephrol 1997;5:180-188.
16. Vernier RL, Steffes MW, Sissons-Ross S, Mauer M: Heparan sulfate proteoglycan in the glomerular basement membrane in type I diabetes mellitus. Kidney Int 1992;41:1070-1080.
17. Van den Born J, van den Heuvel LPWJ, Bakker MAH, Veerkamp JH, Assman KJM, Weening JJ, Berden JHM: Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int 1993;43:454-463.
18. Van den Born J, Gunnarson K, Bakker MAH, Kjellen L, Kusche-Gullberg M, Maccarana M, Berden JHM, Lindahl U: Presence of N-unsubstituted glucosamine units in native heparan sulfate revealed by a monoclonal antibody. J Biol Chem 1995;270:31303-31309.
19. Tamsma JT, van den Born J, Bruijn JA, Assmann KJM, Weening JJ, Berden JHM, Wieslander J, Schrama E, Hermans J, Veerkamp JH, Lemkes HHPJ, van der Woude FJ: Expression of glomerular extracellular matrix components in human diabetic nephropathy: Decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 1994;37:313-320.
20. Van der Piji JW, Daha MR, van den Born J, Verhagen NA, Lemkes HH, Bucala R, Berden JH, Zwinderman AH, Bruijn JA, van Es LA, van der Woude FJ: Extracellular matrix in human diabetic nephropathy: Reduced expression of heparan sulphate in skin basement membrane. Diabetologia 1998;41:791-798.
21. Iozzo RV, Cohen IR, Grässel S, Murdoch AD: The biology of perlecan: The multifaceled heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 1994;302:625-639.
22. Groffen AJ, Ruegg MA, Dijkman H, van de Velden TJ, Buskens CA, van den Born J, Assmann KJ, Monnens LA, Veerkamp JH, van den Heuvel LP: Agrin is a major heparan sulfate proteoglycan in the human glomerular basement membrane. J Histochem Cytochem 1998;46:19-27.
23. Halfter W, Dong S, Schurer B, Cole GJ: Collagen XVIII is a basement membrane heparan sulfate proteoglycan. J Biol Chem 1998;273: 25404-25412.
24. Raats CJ, Bakker MA, Hoch W, Tamboer WP, Groffen AJ, van den Heuvel LP, Berden JH, van den Born J: Differential expression of agrin in renal basement membranes as revealed by domain-specific antibodies. J Biol Chem 1998;273: 17832-17838.
25. Van Del NF, van den Born J, Tamsma JT, Verhagen NAM, Berden JHM, Bruijn JA, Daha MR, van der Woude FJ: Effects of high glucose on the production of heparan sulfate proteoglycan by human mesangial and glomerular visceral epithelial cells in vitro. Kidney Int 1996;49: 1079-1089.
26. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984;74:1143-1155.
27. Kagami S, Border WA, Miller DA, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-2437.
28. van Det NF, Tamsma JT, van den Born J, Verhagen NAM, van den Heuvel LPWJ, Lowik CWGM, Berden JHM, Bruijn JA, Daha MR, van der Woude FJ: Differential effects of angiotensin II and transforming growth factor β on the production of heparan sulfate proteoglyean by mesangial cells in vitro. J Am Soc Nephrol 1996;7:1015-1023.
29. Gambaro G, Venturini AP, Noonan DM, Fries W, Re G, Garbisa S, Milanesi C, Pesarini A, Borsatti A, Marchi E, Baggio B: Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 1994;46: 797-806.
30. Gambaro G, Cavazzana AO, Luzi P, Piccoli A, Borsatti A, Crepaldi G, Marchi E, Venturini AP, Baggio B: Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 1992;42:285-291.
31. Ceol M, Nerlich A, Baggio B, Anglani F, Sauer U, Schleicher E, Gambaro G: Increased glomerular α1(IV) collagen expression and deposition in long-term diabetic rats is prevented by chronic glycosaminoglycan treatment. Lab Invest 1996;74:484-495.
32. Oshima Y, Isogai S, Mogama K, Ohuchi H, Ohe K: Protective effect of heparin on renal glomerular anionic sites of streptozotocin-injected rats. Diab Res Clin Pract 1995;25: 83-89.
33. Oturai PS, Rasch R, Hasseleger E, Johansen PB, Yokoyama H, Thomsen MK, Myrup B, Kofoed-Enevoldsen A, Decken T: Effects of heparin and aminoguanidine on glomerular basement membrane thickening in diabetic rats. Acta Pathol Microbiol Scand 1996;104:259-264.
34. Gambaro G, Baggio B: Glycosaminoglycans: A new paradigm in the prevention of proteinuria and progression of glomerular disease. Nephrol Dial Transplant 1996;11: 762-764.
35. Gambaro G, Barbanti M, Marchi E, Baggio B: Therapy with glycosaminoglycans in nephrology; in Harenberg J, Casu B (eds): Nonanticoagulant Actions of Glycosaminoglycans. New York, Plenum Press, 1996, pp 281-286.
36. Myrup B, Hansen PM, Jensen T, Kofoed-Enevoldsen A, Feldt-Rasinussen B, Gram J, Kluft C, Jespersen J, Deckert T: Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet 1995;345:421-422.
37. Tamsma JT, van der Woude FJ, Lemkes HHPJ: Effect of sulfated glycosaminoglycans on albuminuria in patients with overt diabetic (type-1) nephropathy. Nephrol Dial Transplant 1996;11:182-185.
38. Van der Pijl JW, van der Woude FJ, Geelhoed-Duijvestijn PHLM, Fröhlich M, van der Meer FJM, Lemkes HHPJ, van Es LA: Danaparoid sodium lowers proteinuria in diabetic nephropathy. J Am Soc Nephrol 1997;8:456-462.
39. Solini A, Carraro A, Barzon I, Crepaldi G: Therapy with glycosaminoglycans lowers albumin excretion rate in non-insulin-dependent diabetic patients with microalbuminuria. Diab Nutr Metab 1994;7:304-307.
40. Skrha J, Perusicova J, Pontuch P, Oksa A: Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients. Diab Res Clin Pract 1997;38:25-31.
41. Poplawska A, Szclachowska M, Topolska J, Wysocka-Solowie B, Kinalska I: Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro- or macroalbuminuria. Diab Res Clin Pract 1997;38: 109-114.
42. Dedov I, Shestakova M, Vorontzov A, Palazzini E: A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrol Dial Transplant 1997;12:2295-2300.
43. Poplawska A, Toplska J, Kinalska I, Grimaldi M: A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients. Curr Med Res Opin 1997;13:539-545.
44. Van der Pijl JW, Lemkes HHPJ, Fröhlich M, van der Woude FJ, van der Meer FJM, van Es LA: Effect of danaparoid sodium on proteinuria, von Willebrand factor, and hard exudates in patients with diabetes mellitus type II. J Am Soc Nephrol 1999;10:1331-1336.
45. Fioretto P, Mauer M, Brocco E: Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1995;39:1569-1576.
46. Van der Pijl JW, van der Woude FJ, Swart W, van Es LA, Lemkes HHPJ: Effect of danaparoid sodiun? on hard exudates in diabetic retinopathy. Lancet 1997;350:1743-1745.
47. Paques M, Massin P, Gaudric A: Growth factors and diabetic retinopathy. Diabet Metabol 1997;23: 125-130.
48. Klein R, Klein BEK: Diabetic eye disease. Lancet 1997;350:197-204.